SG Americas Securities LLC Grows Stock Holdings in Replimune Group, Inc. $REPL

SG Americas Securities LLC increased its position in Replimune Group, Inc. (NASDAQ:REPL) by 868.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 98,731 shares of the company’s stock after buying an additional 88,532 shares during the quarter. SG Americas Securities LLC’s holdings in Replimune Group were worth $414,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Griffin Asset Management Inc. purchased a new position in shares of Replimune Group in the third quarter valued at about $82,000. Osaic Holdings Inc. grew its position in shares of Replimune Group by 26,006.0% during the second quarter. Osaic Holdings Inc. now owns 26,106 shares of the company’s stock worth $243,000 after purchasing an additional 26,006 shares in the last quarter. Squarepoint Ops LLC raised its stake in Replimune Group by 394.0% during the 2nd quarter. Squarepoint Ops LLC now owns 67,929 shares of the company’s stock valued at $631,000 after purchasing an additional 54,178 shares during the period. Tower Research Capital LLC TRC grew its holdings in Replimune Group by 2,020.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock valued at $90,000 after buying an additional 9,235 shares in the last quarter. Finally, Exome Asset Management LLC raised its position in shares of Replimune Group by 34.9% during the second quarter. Exome Asset Management LLC now owns 397,846 shares of the company’s stock valued at $3,696,000 after buying an additional 103,000 shares during the last quarter. 92.53% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Christopher Sarchi sold 5,208 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $47,392.80. Following the completion of the sale, the insider owned 123,088 shares in the company, valued at approximately $1,120,100.80. This trade represents a 4.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kapil Dhingra sold 3,169 shares of Replimune Group stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $10.40, for a total transaction of $32,957.60. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 25,625 shares of company stock worth $257,607. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on REPL shares. HC Wainwright upgraded shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Monday, October 27th. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $3.00 to $13.00 in a report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a report on Monday, October 20th. Finally, Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and increased their target price for the company from $4.00 to $18.00 in a research report on Monday, October 20th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $9.75.

Replimune Group Price Performance

NASDAQ:REPL opened at $7.71 on Monday. The firm has a market capitalization of $604.77 million, a price-to-earnings ratio of -2.23 and a beta of 0.72. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31. The business has a 50 day simple moving average of $9.19 and a 200-day simple moving average of $7.44. Replimune Group, Inc. has a 1 year low of $2.68 and a 1 year high of $14.80.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Equities analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.